Likun H. Chen

Guangdong Provincial Key Laboratory Of Thermal Management Engineering & Materials
Shenzhen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Author Correction: A ductile solid electrolyte interphase for solid-state batteries.

Author Correction: A ductile solid electrolyte interphase for solid-state batteries.

Journal: Nature

Published: July 29, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

A Chemical-Potential-Driven Self-Mitigation Mechanism during Calendar Aging.

A Chemical-Potential-Driven Self-Mitigation Mechanism during Calendar Aging.

Journal: Nano letters

Published: April 23, 2026

Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer.

Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer.

Journal: Journal of translational medicine

Published: March 13, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Single-crystal orientation lithium for ultra-stable all-solid-state batteries.

Single-crystal orientation lithium for ultra-stable all-solid-state batteries.

Journal: National science review

Published: August 25, 2025

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

Journal: ESMO open

Published: August 18, 2025

Suppressing concentration polarization in lithium battery composite polymer electrolytes via piezo-assisted electromechanical coupling effect.

Suppressing concentration polarization in lithium battery composite polymer electrolytes via piezo-assisted electromechanical coupling effect.

Journal: Nature communications

Published: August 15, 2025

Electron Percolating Shielded Interlayer Enabling Ultrastable All-Solid-State Lithium Metal Batteries.

Electron Percolating Shielded Interlayer Enabling Ultrastable All-Solid-State Lithium Metal Batteries.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: August 12, 2025

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Journal: Cancer

Published: August 07, 2025

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

Journal: EClinicalMedicine

Published: July 21, 2025

Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases.

Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases.

Journal: NPJ precision oncology

Published: July 21, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026